This article explores new data from recent studies addressing the role of coinfections in immune activation in HIV-1-infected patients, with a focus on immune reconstitution inflammatory syndrome (IRIS), an aberrant inflammatory response occurring shortly after antiretroviral therapy (ART) initiation.
INTRODUCTION
Chronic HIV infection more than any other infectious disease is a disease of coinfections, as the HIV virus cripples the immune system and allows reactivation of dormant pathogens or increases susceptibility to exogenous pathogen [1] . These coinfections fuel further the immune activation that characterizes HIV infection, even after initiation of antiretroviral therapy (ART). From the pre-ART era, it was apparent that opportunistic infections including malignancies triggered by infectious agents like Kaposi's sarcoma and Epstein-Barr virus (EBV)associated lymphomas were the hallmark of HIV [2] . Although in the current era morbidity and mortality by opportunistic diseases has decreased, albeit still significant [3, 4] , infections such as cytomegalovirus (CMV), tuberculosis (TB), hepatitis C and B, and human papillomavirus are still at center stage of health issues in treated chronic HIVinfected persons [5] and remain important factors for the pathogenesis of serious non-AIDS events (SNAEs) [6] as discussed in other reviews in this issue of Current Opinion in HIV and AIDS.
], the sobering reality is that many patients present late at diagnosis or treatment initiation in both resource-limited and resource-rich settings [8] . According to US statistics, 23% of patients get diagnosed with HIV at stage 3 (AIDS) [9] , and recent studies from South Africa [10 & ] and Europe [11] report similar statistics with a persistently high proportion of patients presenting late for therapy initiation. The state of advanced immunosuppression in which HIV-infected individuals present with at diagnosis makes these patients highly vulnerable to a variety of opportunistic infections, in particular those that live in endemic areas.
In this issue of Current Opinion in HIV and AIDS, dedicated to immune activation in HIV, several reviews have discussed coinfections mostly highlighting their important roles in SNAEs as well as the role of coinfections in sexual and vertical transmission. In this review, the discussion will focus on acute inflammation and immune activation following ART initiation in the form of immune reconstitution inflammatory syndrome or IRIS and briefly review recent data on contribution of chronic viral infection in immune activation in treated patients.
COINFECTIONS IN HIV
Coinfections are a main factor driving increased morbidity and mortality in HIV-infected patients. Estimates from the WHO indicate that approximately one-fourth of the 1.5 million deaths of HIV-infected patients is attributed to TB [12] . Moreover, in both Europe and Northern America, approximately 10% of patients present for therapy initiation with an AIDS-defining illness, most of them representing infections [11] . Among people with HIV in the USA, about 25% are coinfected with hepatitis C virus (HCV) and near 10% are coinfected with hepatitis B virus, whereas these percentages are higher in areas where preventive measures and therapy options are less advanced [13] [14] [15] [16] . Cryptococcal antigen prevalence among persons with CD4 þ counts below 100 cells/ml averages 7.2% (95% confidence interval, 6.8-7.6%) in 37 studies of 14 815 patients from low-and middle-income countries [17] . Given the immune suppression state of HIV patients, these and other coinfections can present with a wide range of clinical syndromes with atypical manifestations that pose challenges in diagnosis and clinical management, representing a substantial burden for the public health system.
With respect to chronic viral infections, CMV seroprevalence in HIV-infected population is high ranging from 75 to 90% [18 & ]. In Africa, estimates of herpes simplex virus (HSV)-1 and HSV-2 seroprevalence among adult HIV-infected individuals vary from 65 to 90% and rates above 85% have also been reported for CMV and EBV in HIV-infected adult individuals from several African countries [19] . HIV-1 infected individuals have higher rates of HSV-2 antibodies compared with HIV-1 uninfected persons: 85% among HSV-2 and HIV-1 coinfected individuals in sub-Saharan Africa, 65% among MSM in San Francisco, and 80% of HIV-1 infected men in combined data from a US national survey [20] . It is thus apparent that the majority of HIV-infected persons have a coinfection at a minimum at some point during their course.
A particularly intriguing pathology related to immune activation in HIV patients with coinfections is a reaction referred to as IRIS, which can affect approximately 20% of these patients, despite effective viral suppression induced by ART [21, 22] . The initial description of IRIS preceded combination ART. A cluster of Mycobacterium avium complex lymphadenitis, in some patients with fever, was described in an Australian cohort treated with zidovudine monotherapy and was thought to be immune restoration disease as many patients also converted their skin test (delayed type hypersensitivity) to reactive [23] . IRIS is considered an aberrant immune response to a known and treated (paradoxical) or occult pre-ART (unmasking) pathogen, and despite overall control of the pathogen (cultures in paradoxical are frequently negative), it is characterized by tissue-destructive inflammation and arises as functional CD4 þ T cells against the opportunistic pathogen emerge [24, 25] . Mycobacterial IRIS is commonly manifested by necrotizing
KEY POINTS
The vast majority of HIV-infected persons have one or more coinfections (including CMV and other herpesviruses, HCV or TB) at least at some point during their course. These coinfections play an important role in chronic immune activation and pathogenesis of SNAEs but the mechanisms are not always clear.
A significant proportion of HIV-infected persons get diagnosed at late stages of disease frequently with an opportunistic disease such as TB. Earlier initiation of ART could prevent most opportunistic diseases.
IRIS represents a dysregulated inflammatory response that occurs shortly after ART initiation in HIV patients with lymphopenia and infections and is characterized by profound T-cell effector function recovery and innate immune activation ( Fig. 2) . Understanding better the mechanisms of IRIS will help designtargeted interventions. lymphadenopathy ( Fig. 1a and b ), worsening systemic symptoms including fevers, or respiratory symptoms [26] . Cryptococcal IRIS frequently affects the central nervous system and can lead to inflammation and increased intracranial pressure and can be life threatening [27] .
Understanding key immune determinants of the clinical outcomes in coinfections with HIV, both early after ART initiation and during chronic ART, is critical for driving development of innovative therapeutic strategies.
RECENT FINDINGS IN IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME

Tuberculosis
Studies in the past had highlighted an important role for mycobacterial antigen-driven expansion of TB-specific CD4 þ T cells in TB-IRIS [28-30] ( Fig. 1c  and d ). The granulocytic activity of natural killer (NK) cells was also described as important predictor of paradoxical TB-IRIS [31] . In a recent study, the role of T cells was further explored by Haridas et al.
[32 && ] who found that high pre-ART T-cell frequencies of HLA-DR, CD45RO, CCR5 and OX40 expressing CD4 þ T cells, and Fas effector memory CD8 þ T cells were associated significantly with TB-IRIS development. Interestingly, after ART treatment initiation, the CD4 þ T-cell memory was skewed toward effector-memory phenotype [32 && ]. In another study, it was postulated that low CD8 þ T-cell activation (HLA-DR þ /CD38 þ ) could be a predisposing factor of both early and late-onset TB-IRIS events and that late but not early-onset IRIS showed a shift from memory to effector CD8 þ and CD4 þ T cells after ART initiation [33] . Wilkinson et al. [34 & ] also studied the effector function of TB-specific CD4 þ T cells and demonstrated an increase in interferon (IFN)g response as well as in perforin 1 and granzyme B expression in heat-killed H37Rv-stimulated human peripheral blood mononuclear cells (PBMCs) from paradoxical TB-IRIS patients compared with HIV-TB coinfected non-IRIS patients further highlighting the effector function of TBspecific cells.
Many cytokines that were elevated in patients with TB-IRIS had long suggested an important role for innate cells of myeloid origin [22, 35] , and ], the role of monocytes in TB-IRIS was further delineated. Specific proinflammatory biomarkers of innate and myeloid cell activation appeared to be elevated in TB-IRIS patients and more importantly a clear activation of innate responses was seen in TB-HIV coinfected patients pre-ART who had received less than 4 weeks of anti-TB therapy. In addition, the potential predictive value of CD14 þþ CD16 À monocyte frequency and plasma levels of C-reactive protein, tumor necrosis factor (TNF), interleukin (IL-6), tissue factor, and soluble (s) CD14 for TB-IRIS were highlighted in this and other studies [38 && ,39,40 & ]. The monocytes seem to be directly involved in production of proinflammatory cytokines such as TNF and IL-6 [39]. These cytokines, core participants in immunopathology of IRIS, could also potentially represent important targets for intervention as suggested in a recent case series of patients with mycobacterial IRIS that was refractory to corticosteroids, who were treated with infliximab [41 & ]. Furthermore, IL-18 and CXCL10 have been presented as candidate biomarkers for predicting both paradoxical and unmasking TB-
], suggesting a potential role of the inflammasome, which was further supported in a study of gene array analysis pre/post-ART in patients with TB who developed paradoxical TB-IRIS [42 && ]. This observation should be further followed up by studies dissecting the mechanisms and assessing how a high antigen load during T-cell functional recovery may trigger inflammasome activation.
In a novel study that primarily focused on a mouse model of TB studying the role of IL-27 in TB, in-vitro Mycobacterium tuberculosis-stimulated PBMCs from patients with paradoxical TB-IRIS, we found to transcribe more IL-27p28 than PBMCs from HIV/TB coinfected patients without IRIS ]. This is of particular interest as IL-27 is produced by myeloid cells, and may represent an important immune checkpoint in TB [44] .
In a prospective cohort study at 22 public clinics and the main public hospital in Gaborone, Botswana, the immunological profile at baseline and week 4 after ART initiation in ART-naïve adults (aged !21 years) with advanced HIV (CD4 þ cell counts 125 cells/ml) and pulmonary TB was assessed [45 && ]. A main comparison was made between TBassociated IRIS or early mortality with those who survived without an IRIS diagnosis (controls) in the 6 months after ART initiation. Patients with paradoxical TB-IRIS had decreased pre-ART inflammatory profile but the groups of IRIS and deaths were distinguished by sharply divergent recovery of the adaptive immune system (TB-IRIS patients had similar increases in CD4 þ cell count and purified protein derivative-specific immune responses with controls, whereas those who died had minimal immune recovery despite virological control during ART). These data suggest that patients who die of TB despite ART initiation are distinct from patients who go on to develop TB-IRIS and may not benefit or may be harmed by strategies to immunosuppress HIV/TB coinfected patients, but may in fact benefit for immune-boosting strategies [45 && ]. The results of the ongoing randomized controlled clinical trial of prednisone for prevention of TB-IRIS will probably shed light on this specific issue [Preventing TB-IRIS in high-risk patients: a randomized placebocontrolled trial of prednisone (pred-ART), Clinical-Trials.gov Identifier: NCT01924286].
A consistent observation has been that IRIS is more common when TB was pretreated for a shorter interval prior to ART initiation suggesting that longer treatment of TB could ameliorate the complication of IRIS [39, 46, 47] . Several randomized controlled trials in mostly resource-limited settings though have showed that overall mortality was higher with delaying ART in patients with lower CD4 þ T-cell counts despite the higher incidence of IRIS [48] [49] [50] . A recent published systematic review and meta-analysis assessed the effect of early initiation of ART (within 2-4 weeks of TB treatment) on TB/HIV coinfection outcome. Early treatment was shown to be beneficial by reducing all-cause mortality, but it did increase the risk for TB-IRIS and death related to TB-IRIS in these patients [51] .
Finally, in the international multicenter randomized study conducted by the INSIGHT START group, initiation of ART in naïve-treated HIV-positive individuals with CD4 þ T-cell count more than 500 cells/ml compared with deferred initiation in 350 cells/ml resulted in reduced risk for TB infection both in high and low-moderateincome countries [52] . In addition, higher percentage of patients achieved long-term low HIV RNA load as well as higher mean CD4 þ cell count. All these factors could influence the predisposition for paradoxical or unmasking IRIS associated with TB infection if widespread early initiation of ART is achieved.
Cryptococcus
Many studies have focused on exploring specific immune responses in cryptococcal meningitis, which remains the leading cause of mortality among IRIS cases and a significant cause of mortality in HIV-infected individuals.
In a study conducted in sub-Saharan Africa, an area that holds the highest burden of cryptococcal meningitis-related death among the HIV population, Boulware et al. [53 && ] definitively showed that deferring ART treatment for 5 weeks after cryptococcal meningitis diagnosis compared with early initiation at 1-2 weeks significantly improves survival. Interestingly, the hazard ratio (HR) was even higher among patients with fewer white cells in their cerebrospinal fluid (CSF) at randomization (<5 per cubic millimeter). Cryptococcal IRIS events did not significantly differ between the earlier ART group and the deferred ART group. Cryptococcal meningitis-related deaths occurred between 2 and 5 weeks after diagnosis (10 in the earlier ART group and three in the deferred ART group) and were judged to be caused by the initial cryptococcosis rather than separate, distinct cryptococcal-IRIS events even though they hypothesized that earlier ART is most harmful in high-risk persons with a predisposition to cryptococcal IRIS [i.e., those with low CSF white cell count (WCC)] [53 && ]. In their cohort, the COAT Team provided evidence that early ART initiation in cryptococcal meningitis increased CSF cellular infiltrate (CSF WCC !5/ml) by day 14 as well as CSF IL-13, sCD14, sCD163, and ] demonstrated that cytokine responses of IFNg (Th1), IL4 and IL10 (Th2), and IL17 (Th17) in the CSF of patients with HIV-associated cryptococcal meningitis were linked to increased macrophage activation, more rapid clearance of cryptococci from CSF, and survival at 2 weeks with IL-6 to contribute the most to this protective effect. Strikingly, chemokines consisting primarily of monocyte chemotactic protein-1 and macrophage inflammatory protein-1a were identified as predictive markers of IRIS.
With respect to unmasking cryptococcal meningitis or TB, in a clinical, open-label, randomized controlled trial conducted in Tanzania and Zambia, investigators tried to assess the effect of advanced healthcare delivery strategy as well as the addition of screening for Cryptococcus in ART-naïve HIV-infected individuals' outcome [17] . Although most participants presented with advanced stage 3 HIV infection, prompt ART initiation strategy, screening for serum cryptococcal antigen and TB, supplementation of clinicbased care to the standard care with a short period of adherence support, and monitoring in the community reduced all-cause mortality by nearly 30% [17] . Of note, even in the group treated for cryptococcal infection, the adjusted rate of mortality remained higher than cryptococcal antigen-negative individuals.
Viral immune reconstitution inflammatory syndrome
Viral IRIS remains less well investigated and may have different pathogenesis aspects that are not clear to date. Evidence for a role of high antigen load has been observed in both hepatitis flares [57] and in Kaposi sarcoma IRIS after ART initiation [58] , but studies looking specifically at viral IRIS pathogenesis have not been published recently.
Gianella et al. [59 & ] investigated CMV vaginal shedding longitudinally among women coinfected with HIV, HSV-2, and CMV, who started ART and were participants in the placebo-controlled trial of HSV-2 suppression with acyclovir in Uganda. Based on their results, younger age as well as higher pre-ART HIV RNA viral load (>100 000 copies/ml) were associated with increased frequency of CMV shedding. Importantly, prevalence of CMV DNA shedding was higher after ART initiation, with peak being observed in months 2-4 post-ART suggesting the possibility of an immune reconstitution-related reactivation of the virus. CMV can cause clear IRIS events upon ART initiation as highlighted in two recent case reports of acute appendicitis and sialadenitis occurring shortly after ART initiation [60, 61] .
There is also evidence that ART initiation can increase the rate of HSV-2 shedding and genital ulcer disease during the first 1-3 months of treatment, particularly among women with low CD4 þ cell counts at ART initiation, possibly as a form of immune reconstitution [62] . However, a recently published study conducted in Burkina Faso in women living with HIV-1, coinfected with HSV-2, showed that cervico-vaginal HSV-2 shedding declined while on ART along with a reduction of genital ulcer disease, with the latter being associated mainly with HIV-1 viral suppression [63] .
With respect to clinical trials attempting to prevent IRIS, a large randomized double-blinded controlled clinical trial in immunosuppressed (CD4 þ <100 cells/ml) patients testing maraviroc versus placebo, with the goal to decrease trafficking of effector cells to tissues thus preventing inflammation, failed to prevent IRIS or decrease severity of IRIS events [64 && ]. Of note, maraviroc use did not affect the outcome of opportunistic infections in the cohort, many of who suffered from TB.
COINFECTIONS: ONGOING INFLAMMATION IN CHRONIC HIV INFECTION
The role of coinfections in chronic-treated HIV infection and their contribution in morbidity and mortality and pathogenesis of SNAEs has been highlighted in other reviews in this issue of Current Opinion in HIV and AIDS. The presence of opportunistic infections at initial presentation of HIVinfected patients is not rare yet their contribution in higher residual chronic inflammation and SNAEs after long treatment with ART has not been systematically studied.
In a South African HIV-infected population study, Sullivan et al. [65] showed that patients with active TB infection have elevated levels of soluble inflammatory biomarkers associated with monocyte activation, as well as surface markers of T-cell activation compared with HIV-monoinfected individuals. They also presented that coexpression of CD38 and HLA-DR on CD4 þ and CD8 þ T cells is higher in HIV-infected individuals with latent TB compared with those with no TB and raised again the issue about more widespread treatment of HIV patients with latent TB infection. The patients with active TB infection had lower CD4 þ T-cell counts, so it was unclear if the higher levels of activation could be attributed to lymphopenia; yet the question remains whether these patients have higher residual inflammation and cellular activation after years of successful ART.
CMV has been systematically studied as a contributing coinfection in aging and cardiovascular disease along with the effect of the virus on immune activation and especially on immune senescence. Lichtner et al. [18 & ] demonstrated that HIV-1infected individuals from Italian Cohort Naive Antiretrovirals (ICONA) study with CMV immunoglobulin G seropositivity, without active CMV disease, were associated with an increased risk of non-AIDS-defining event/death and an adjusted HR of 2.27 for cardiovascular and cerebrovascular diseases. The potential role of CMV-specific immune responses (both T cell and antibodies) in cardiovascular disease has been highlighted in several studies in the past [66] [67] [68] . In an exposurematched, small cross-sectional study of low cardiovascular disease risk (nonsmokers), HIV-infected patients, however, increased carotid intima-media thickness was not associated with CMV seropositivity [69] . The study emphasized the important role of comorbidities but sample size may have been insufficient to detect differences.
The role of CMV has also been implicated in T-cell senescence and aging with accumulation of CD28 À CD57 þ CD8 þ T cells [70] . Lee et al. [71] reported that untreated HIVþ/CMVþ patients had lower proportions of CD28 À CD8 þ cells expressing CD57 and were enriched for less well differentiated CD28 À transitional memory (TTR) CD8 þ T cells relatively to HIV-uninfected CMVþ persons highlighting important differences on T cells between mono and dually infected persons that may have significance in SNAEs. Unfortunately, they did not study these factors between HIVþ/CMVÀ and HIVþ/CMVþ groups. Freeman et al. [72] did compare CMV seropositive and CMV seronegative HIVþ patients and detected CD8 þ T-cell expansion in CMV coinfected patients compared with CMVÀ, along with higher plasma levels of IP-10, TNF-RII, and D-dimer. In addition, coinfection with HIV and CMV resulted in a significantly lower CD4 þ /CD8 þ ratio than was seen among HIV-infected CMV-seronegative patients. Finally, in a small study of HIVþ adults, valganciclovir was efficacious in suppressing CMV DNA and reducing CD8 þ T-cell activation (percentage expressing CD38 þ HLA-DR þ ), suggesting not only that CMV replication contributes to immune activation in coinfected individuals, but also that pharmacologic suppression of CMV may help reverse this process [73] . It remains though unclear if persistent CMV suppression could have clinical benefits.
Regarding the role of other herpesviruses, several studies have attempted to assess the role of HSV-2 coinfection in HIV disease progression providing evidence that genital shedding is a cofactor for increased HIV replication and that acyclovir/valacyclovir could be helpful in HIV suppression at least at the local mucosal level [25, [74] [75] [76] [77] [78] . Redd et al. [79] tried to explore the effect of acyclovir on immune activation status in HIV-1/HSV-2 ART-naïve coinfected women and demonstrated a relatively small decrease of sCD14 but at a significantly faster rate in acyclovir treated compared with the untreated group, independently of HIV viral load and CD4 þ cell count suggesting a role for monocyte activation during HSV-2 reactivation. In ART-treated patients though a randomized controlled trial of valacyclovir for 12 weeks to suppress HSV-2 showed no effect on cellular immune activation or systemic inflammatory markers suggesting that the overall impact on systemic immune activation of treated patients may be small or transient [80] . Prospective clinical trials will contribute to further determine whether HSV suppressive therapies could help in lowering more effectively plasma and genital HIV viral load and local and/or systemic immune activation by using them together with ART in HIV/HSV-2 coinfected patients. Finally, HHV8 may also have an impact in chronic immune activation of chronically treated HIV patients as suggested by a study in 157 patients that reported an independent effect of HHV8 seropositivity on higher C-reactive protein and higher CD4 þ and CD8 þ T-cell activation levels but not on flow dilatation or carotid intima media thickness [81] .
Hepatitis C is an important coinfection that impacts morbidity and mortality in HIV infection and has implications not only for liver disease including cirrhosis and hepatocellular carcinoma but also for extrahepatic comorbidities in HIV [82, 83] . In a recently published retrospective large cohort of 1153 patients, HIV/HCV coinfection was found to be independently associated with cardiovascular events (HR 2.91; 95% confidence interval, 1.19-7.12; P ¼ 0.02) compared with HCV or HIV monoinfection after adjusting for demographic, virologic, and traditional cardiac risk factors [84 && ]. This is consistent with a cross-sectional study from the Multicenter AIDS cohort study (MACS) cohort that found HCV/HIV coinfection to be an independent risk factor for subclinical atherosclerosis assessed by noncontrast computerized tomography (CT) and CT angiography [85] . A small study reported evidence of higher tissue factor activity (measured as microparticles tissue factor), a procoagulant factor, and associated CD4 þ T-cell activation in HCV patients both mono and HIV-coinfected suggesting a potential mechanism of immune activation and coagulopathy that may predispose to cardiovascular disease [86] . In another prospective study, immune activation markers were compared between HIV-monoinfected and HIV/HCV-coinfected (with and without cirrhosis) ART-treated patients with suppressed plasma HIV viremia during 12 months [87] . HIV patients with chronic hepatitis and cirrhosis had higher concentrations of serum sCD14 and IL-6 and incomplete CD4 þ restoration. Although the percentage of activated CD4 þ and CD8 þ T cells and Treg were higher in HIV-infected patients compared with healthy controls, no significant differences were observed among the groups of HIV patients [87] . In a different study, biomarkers of inflammation including IFNa were found to be higher in HCV/HIV-coinfected patients compared with HCV-monoinfected patients but importantly, some decreased after successful sustained virologic suppression of hepatitis C [88] . Decreases in sCD163 and sICAM were also noted 24 weeks after HCV treatment with pegylated IFN/ribavirin in another cohort of 54 patients [89] . It is thus possible that newer, more effective, HCV regimens for HIV patients [90] may favorably impact the chronic immune activation and inflammation of HIV/ HCV-coinfected patients with a potential subsequent decrease not only of liver morbidity and mortality but also of SNAEs in HCV-coinfected persons.
CONCLUSION
Coinfections play a fundamental role in immune activation in all stages of HIV infection. This can range from emergence of IRIS early after ART initiation in patients with advanced disease and opportunistic infection, to higher risk of cardiovascular disease in chronically treated HIV patients with CMV or HCV coinfection and to higher HIV transmission potential in patients with HSV shedding. Better understanding of the immune activation pathways involved in HIV coinfections will be instrumental in designing appropriate therapeutic strategies. Transcriptional profiling of patients with TB who did or did not develop IRIS showed no significant differences at baseline (pre-ART), but as soon as 0.5 weeks post-ART initiation, a signature involving Toll-like receptor and inflammasome genes distinguished the TB-IRIS group. Findings were corroborated by in-vitro experiments blocking MyD88 and caspases 1 that led to decreases in IL-1 production. Immunological profiling at baseline and week 4 after ART initiation in a large cohort of ART-naïve adults with advanced HIV with pulmonary tuberculosis showed that paradoxical TB-IRIS patients had decreased pre-ART inflammatory cytokines like IL-6 with increases after ART that were also associated with CD4 þ increases similar to those observed in non-IRIS survivors, contrary to patients with early mortality who had high IL-6 at baseline and lower CD4 þ increases post-ART. This study highlighted important baseline differences of patients at risk for paradoxical TB-IRIS versus at risk of death early post-ART. 
